Navigation Links
VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia
Date:6/1/2011

LOS ANGELES and PERTH, Australia, June 1, 2011 /PRNewswire/ -- MMRGlobal, Inc. (OTCBB: MMRF) ("MMR") and VisiInc PLC (VZJ) (www.deutsch-boerse.com) have entered into an agreement to launch MMRGlobal's patented consumer and professional health IT products and services, including MMRPro for healthcare professionals (www.mmrprovideos.com) and the MyMedicalRecords Personal Health Record (PHR) (www.mmrvideos.com), on the Visi™ platform utilizing the Vistime product.  Vistime is a multi-file format, real-time 3D viewer for retrieval and viewing of large files, including medical imaging systems such as MRIs, scans and sonograms, over any Internet connection, including dial-up.  The system allows physicians and patients to view and discuss medical records including radiology images in an online meeting format, making MMR's MyMedicalRecords one of the world's most functional Personal Health Records systems that allows collaboration of multiple specialists in real time.

MMR will also integrate the Visi platform into its offerings on a global basis. The VisiInc technology will enable MMR users to render and distribute large multi-dimensional visual files within the MMR interface, including digital medical media such as MRI and CAD files at lightning-fast speed without any resolution degradation or enterprise infrastructure barrier regardless of Internet connection, including dial-up ("Vistime," www.vistime.com). 

With current and future planned products MMR and Visi see this as an opportunity in what is estimated to be a $2.4b market.

Jacques Blandin, Chief Executive Officer and Founder of VisiInc PLC, said, "Vistime is the world's easiest to use multi-file format, real-time 3D viewer for powerful collaboration of medical records, including radiological images, using Visi rapid visual rendering capabilities. Working with MMR, our plan is to offer a MyMedicalRecords Personal Health Record globally.  VisiInc will offer the product in Australia through its subsidiary Firmware Technologies. Integrating the Visi technology with the MMR PHR will allow consumers anywhere to simultaneously view and explore Personal Health Records including multi-dimensional data visualizations of any file type of any size, in real-time."

The Visi MMR relationship responds to that agenda and can represent the beginning of a next generation of Personal Health Management Systems for consumers and healthcare professionals," stated Robert H. Lorsch, Chairman and CEO of MMRGlobal, Inc.

About VisInc PLC

In May 2011 VisiInc PLC announced the completion of its merger with Firmware Technologies Inc and its subsequent quotation on the Frankfurt Stock Exchange. VisiInc.com

Through it's evolutionary Visi™ platform, VisiInc operates Vistime. Vistime is rapidly capturing global market share of major verticals such as Healthcare, Government, Engineering and Architecture, Mining, Oil & Gas, Exploration, Energy, Education, Advertising & Media and online Video Conferencing. Visi, the next evolution in visual communication, is capable of delivering solutions in both the physical and virtual environment in 3D. Vistime has been designed to integrate with the existing product offerings of the world's leading web collaboration and enterprise content management systems, enabling vendors to immediately expand their product capabilities and service offerings through Integrated Product Offerings, White Label and Private Label Offerings and OEM opportunities www.visiinc.com.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups.. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMR Global, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements  

Statements in this press release that are not strictly historical in nature, including future performance, expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements."  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMRGlobal, Inc.'s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Factors that could cause or contribute to such differences include, but are not limited to, outcomes of the agreement between MMRGlobal, Inc. and VisiInc PLC, the risk its products and services are not adopted or viewed favorably by the healthcare community; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; product integration in physician practices and hospitals; timing and volume of sales and installations; length of sales cycles and the installation process; market acceptance of new product introductions; ability to establish and maintain strategic relationships; ability to identify and integrate acquisitions; relationships with licensees; competitive product offerings and promotions; changes in government laws and regulations and future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; acceptance of the Company's marketing and promotional campaigns; risks related to a security breach by third parties; maintaining, developing and defending our intellectual property rights including those pertaining to our biotechnology assets; risks associated with recruitment and retention of key personnel; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the United States Securities and Exchange Commission. Additionally, we are a developing early-stage company and many variables can affect revenues and/or projections, including factors out of our control. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. 

ONLINE INFORMATION

http://www.visiinc.com
http://www.vistime.com

http://www.mmrglobal.com
http://www.mymedicalrecords.com
www.mmrprovideos.com
http://www.mmrtheater.com

VisiInc Contact:
Glenn Weiland, Vice President Global Communications VisiInc.com
m +61408909553
e   glenn.weiland@visiinc.com

MMRGlobal Contact:
Michael Selsman
Public Communications Co.
310-553-5732
ms@publiccommunications.biz


'/>"/>
SOURCE VisiInc PLC; MMRGlobal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... CENTENNIAL, Colo. , Feb. 5, 2016  As ... about health. The multitude of recommended screenings and tests ... healthy aging a priority. However, for the majority of ... of proactive health planning. For the 37.5 million American ... time like the present to make hearing health a ...
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
(Date:2/5/2016)... ... 05, 2016 , ... The American public tends to feel uncomfortable about drinking ... regular municipal or well water. The recent experience with lead contaminated water in Flint, ... long way toward increasing public acceptance of recycled waste water as drinking water. ...
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
Breaking Medicine News(10 mins):